

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability								
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Set of samples 1															
(81) Digoxin					128			0					128	127	99%
Samples and groups		[nmol/L]													
Sample A1		2,14	0,28	13	128			0	CRV	2,141	0,021	36%	1,37	2,92	128 127 99%
(1) Abbott		1,80	0,13	7,2	33	0									33
(12) Beckman Coulter		2,28	0,12	5,0	13	0									13
(29) Siemens (DPC)		2,25	0,22	9,6	8	0									8
(58) Beckman Coulter (Olympus)		2,32	0,17	7,2	11	0									11
(60) Roche		2,15	0,18	8,5	41	0									41
(179) Siemens (Bayer)		2,39	0,18	7,5	18	0									18
Other					4	0									4
									1x 15, 3x 149						
Sample B1		2,54	0,31	12	128			0	CRV	2,555	0,030	36%	1,63	3,48	128 127 99%
(1) Abbott		2,19	0,13	5,9	33	0									33
(12) Beckman Coulter		2,73	0,15	5,4	13	0									13
(29) Siemens (DPC)		2,58	0,39	15	8	0									8
(58) Beckman Coulter (Olympus)		2,75	0,24	8,6	11	0									11
(60) Roche		2,56	0,19	7,4	41	0									41
(179) Siemens (Bayer)		2,82	0,12	4,1	18	0									18
Other					4	0									4
									1x 15, 3x 149						
(82) Theophylline					89			0					89	88	99%
Samples and groups		[µmol/L]													
Sample A1		109	7,8	7,2	89			0	CRV	110,8	1,1	24%	84,2	138	89 89 100%
(1) Abbott		105	6,3	6,0	23	0									23
(12) Beckman Coulter		103	6,6	6,5	8	0									8
(29) Siemens (DPC)		114	11	9,7	7	0									7
(58) Beckman Coulter (Olympus)		106	6,9	6,5	6	0									6
(60) Roche		110	5,5	5,0	30	0									30
(179) Siemens (Bayer)		117	4,0	3,4	11	0									11
Other					4	0									4
									1x 149, 3x 166						
Sample B1		66,1	4,9	7,5	89			0	CRV	66,94	0,67	24%	50,8	83,1	89 88 99%
(1) Abbott		65,4	5,1	7,9	23	0									23
(12) Beckman Coulter		61,2	3,6	5,9	8	0									8
(29) Siemens (DPC)		67,5	13	19	7	0									7
(58) Beckman Coulter (Olympus)		62,9	6,3	10	6	0									6
(60) Roche		66,5	2,8	4,3	30	0									30
(179) Siemens (Bayer)		72,7	6,3	8,7	11	0									11
Other					4	0									4
									1x 149, 3x 166						

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(83) Primidone					9							9	9	100%									0
Samples and groups	[µmol/L]																						
Sample A1		47,8	4,1	8,5	9	CVP	47,8	5,0	24%	36,3	59,3	9	9	100%									0
(999) another manufacturer		47,2	5,3	11	7							7											
Other					2							2											
						1x 60, 1x 998																	
Sample B1		43,9	4,4	10	9	CVP	43,9	5,5	24%	33,3	54,5	9	9	100%									0
(999) another manufacturer		42,2	7,4	18	7							7											
Other					2							2											
						1x 60, 1x 998																	
(84) Phenobarbital					28							28	28	100%									0
Samples and groups	[µmol/L]																						
Sample A1		64,5	4,7	7,4	28	CVP	64,5	2,2	20%	51,6	77,4	28	28	100%									0
(1) Abbott		65,7	4,8	7,2	11							11											
(60) Roche		62,5	3,3	5,3	9							9											
(999) another manufacturer		65,3	4,2	6,4	5							5											
Other					3							3											
						2x 58, 1x 75																	
Sample B1		95,3	6,3	6,6	28	CVP	95,3	2,9	20%	76,2	115	28	28	100%									0
(1) Abbott		97,7	6,1	6,3	11							11											
(60) Roche		91,8	2,7	2,9	9							9											
(999) another manufacturer		95,4	2,4	2,5	5							5											
Other					3							3											
						2x 58, 1x 75																	
(85) Phenytoin					46							46	45	98%									0
Samples and groups	[µmol/L]																						
Sample A1		61,8	4,1	6,6	46	CVP	61,8	1,5	20%	49,4	74,2	46	46	100%									0
(1) Abbott		63,3	2,7	4,3	13							13											
(60) Roche		60,1	2,0	3,4	14							14											
(999) another manufacturer		60,4	4,4	7,3	5							5											
Other					14							14											
						2x 12, 3x 29, 3x 58, 1x 75, 2x 149, 1x 166, 2x 179																	
Sample B1		53,6	2,6	4,9	46	CVP	53,6	0,95	20%	42,8	64,4	46	45	98%									0
(1) Abbott		53,3	2,6	4,9	13							13											
(60) Roche		53,5	2,1	3,9	14							14											
(999) another manufacturer		53,7	0,70	1,3	5							5											
Other					14							14											
						2x 12, 3x 29, 3x 58, 1x 75, 2x 149, 1x 166, 2x 179																	
(86) Carbamazepin					65							65	60	92%									0
Samples and groups	[µmol/L]																						
Sample A1		9,32	0,99	11	65	CVP	9,32	0,30	20%	7,45	11,2	65	60	92%									0
(1) Abbott		9,33	0,60	6,5	20							20											
(29) Siemens (DPC)		8,68	0,77	8,9	6							6											
(60) Roche		9,06	1,1	12	18							18											
(179) Siemens (Bayer)		9,91	0,75	7,6	5							5											
(999) another manufacturer		10,3	1,0	9,8	5							5											
Other					11							11											
						3x 12, 4x 58, 1x 75, 2x 149, 1x 166																	
Sample B1		26,2	1,9	7,3	65	CVP	26,2	0,58	20%	20,9	31,5	65	64	98%									0

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(86) Carbamazepin	[µmol/L]				65							65	60	92%									0	
Samples and groups																								
Sample B1		26,2	1,9	7,3	65	CVP	26,2	0,58	20%	20,9	31,5	65	64	98%									0	
(1) Abbott		25,6	1,3	5,1	20	0						20												
(29) Siemens (DPC)		24,6	2,3	9,4	6	0						6												
(60) Roche		26,0	1,2	4,5	18	0						18												
(179) Siemens (Bayer)		28,9	3,2	11	5	0						5												
(999) another manufacturer		28,7	1,1	3,9	5	0						5												
Other					11	0						11												
							3x 12, 4x 58, 1x 75, 2x 149, 1x 166																	
(87) Ethosuximide	[µmol/L]				9							9	8	89%									0	
Samples and groups																								
Sample A1		577	61	11	9	CVP	577	75	24%	438	716	9	9	100%									0	
(999) another manufacturer		586	94	16	7	0						7												
Other					2	0						2												
							1x 149, 1x 998																	
Sample B1		192	18	9,4	9	CVP	192	22	24%	145	239	9	8	89%									0	
(999) another manufacturer		187	13	7,2	7	0						7												
Other					2	0						2												
							1x 149, 1x 998																	
(88) Valproic acid	[µmol/L]				84							84	82	98%									0	
Samples and groups																								
Sample A1		216	17	7,8	84	CVP	216	4,5	20%	172	260	84	82	98%									0	
(1) Abbott		204	15	7,2	23	0						23												
(29) Siemens (DPC)		215	11	5,2	8	0						8												
(58) Beckman Coulter (Olympus)		235	25	11	7	0						7												
(60) Roche		216	8,6	4,0	27	0						27												
(179) Siemens (Bayer)		229	15	6,6	10	0						10												
Other					9	0						9												
							1x 0, 3x 12, 1x 75, 3x 149, 1x 166																	
Sample B1		536	34	6,3	84	CVP	536	9,0	20%	428	644	84	83	99%									0	
(1) Abbott		503	34	6,7	23	0						23												
(29) Siemens (DPC)		541	16	2,9	8	0						8												
(58) Beckman Coulter (Olympus)		588	39	6,7	7	0						7												
(60) Roche		540	17	3,1	27	0						27												
(179) Siemens (Bayer)		545	26	4,7	10	0						10												
Other					9	0						9												
							1x 0, 3x 12, 1x 75, 3x 149, 1x 166																	
Set of samples 2																								
(89) Amicacin	[µmol/L]				29							29	26	90%									0	
Samples and groups																								
Sample A2		4,60	0,96	21	29	CVP	4,6	0,44	42%	2,66	6,54	29	27	93%									0	
(1) Abbott		4,86	0,53	11	5	0						5												
(60) Roche		4,37	0,84	19	16	0						16												
Other					8	0						8												
							1x 12, 1x 58, 3x 149, 3x 166																	
Sample B2		24,9	1,5	6,2	29	CVP	24,9	0,70	20%	19,9	29,9	29	28	97%									0	
(1) Abbott		27,3	3,4	12	5	0						5												

